A little background information on EuroMed (now called EuroMED/Canalytics) which Doctor Dalton states will be part of Univec Conglomerate as well as a couple of other affiliated companies.
EuroMED/Canalytics (Doctor Dalton serves on the Board of Directors of this company)
Scheduled to be operational in the second quarter to the third quarter of this year (2020)
Company intends to move current laboratory and DNA research center in Zurich to EuroMed/Canalytics state-of-the-art Extraction Centre in St Gallen, Switzerland. Initially, this 1,000 sqm facility will be equipped to conduct a wide range of cannabis extractions and produce world-class cannabis concentrates, including fractionated distillates. Budget $2.5M to build and equip this facility.
EuroMED/Canalytics state-of-the-art Extraction Centre in St Gallen, Switzerland will be equipped to conduct a wide range of cannabis extractions and produce world-class cannabis concentrates, including fractionated distillates. Construction of the Extraction Centre is expected to begin in 30-45 days and the facility is scheduled to release its first concentrates by the beginning of Q3 (this brings us to the July time frame of 2020).
Build 1st phase (in Israel) of 22,000 sqft of an eventual total of 270,000 sqft, commercial scale GMP & GAP medical cannabis cultivation & manufacturing facility. Initial budget $2.0M. The first phase of building the 22,000 square foot greenhouse facility was scheduled for completion at the end of March, and with planting to begin shortly thereafter.
EurMed/Canalytics is forming a distribution partnership with FutureMed Clinic in Zurich Switzerland
Located at the heart of Zurich, FurtureMed is a private multidisciplinary medical centre that provides medical cannabis derivative products through certified affiliated clinics throughout the EU. FurtureMed strives to offer quality medical CBD/THC, procured by a team of cannabis specialists using the latest medical methods and technology. FurtureMed’s affiliate clinics offer a spacious and pleasant environment. The well-being of their patients is an essential component.
https://secureservercdn.net/160.153.138.177/p...orDeck.pdf
IsraCann Biosciences (ISCNF) stock price .13 cents headquartered in Vancouver, BC
Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer. Isracann is fully funded to execute on over 230,000 sq ft of hybrid greenhouse.
The company is targeting undersupplied domestic demand combined with an immense international market opportunity through Israel’s new medical cannabis export framework for 2020.
Business Model: Four Pillars
Isracann believes in four verticals to leverage its expertise and scale its business
Cultivation
• Architectural design reviewed by Security consultant and Best Practices consultant.
• Designs submission to Israeli Land Authority.
• Application submission to use land as a joint venture.
• Land inspection by the Israeli Land Authority.
• Specific Genetics offtake program designed to provide highest quality gene material within Israel.
• EU GMP certified packing/drying facility targets highest quality product for domestic and export markets.
Manufacturing
• ISL/EU GMP Manufacturing Processes
• Strategic LOI with Israeli manufacturer defines a clear path to in-country revenue.
• Sourcing additional capacity to meet future demand.
• Low-cost production (est. $0.40/gram).
• IMC-GAP/GSP certified for export compliance.
• Production layout offers excellent modularity for irrigation, electrical distribution and maintenance.
• Ideal climate for industrial scale cultivation.
Distribution
• Israel’s massive domestic undersupply drives regional demand.
• Proximity to the EU allows efficient export under new legislation (January 2019).
• Strategic distribution partner provides practical intermediate multinational trans-shipment entry point.
• Product access to Germany, United Kingdom, Poland & Denmark.
• Existing product lines provide access to domestic and export markets.
Branding
• Israel is recognized worldwide as a center for excellence in agronomy, research, genetics, manufacturing and quality assurance.
• Regional expertise allows for branding differentiation that resonates across the globe.
• Brand positioning will focus on high quality “made in Israel Cannabis.”
• Israeli brand will aid positioning of new commercial formulations.
• Build out of Cannabis/CBD product lines will emphasize regional attributes and quality.
https://isracann.com/company/
EuroMED/Canalytics (Doctor Dalton serves on the Board of Directors of this company)
Scheduled to be operational in the second quarter to the third quarter of this year (2020)
Company intends to move current laboratory and DNA research center in Zurich to EuroMed/Canalytics state-of-the-art Extraction Centre in St Gallen, Switzerland. Initially, this 1,000 sqm facility will be equipped to conduct a wide range of cannabis extractions and produce world-class cannabis concentrates, including fractionated distillates. Budget $2.5M to build and equip this facility.
EuroMED/Canalytics state-of-the-art Extraction Centre in St Gallen, Switzerland will be equipped to conduct a wide range of cannabis extractions and produce world-class cannabis concentrates, including fractionated distillates. Construction of the Extraction Centre is expected to begin in 30-45 days and the facility is scheduled to release its first concentrates by the beginning of Q3 (this brings us to the July time frame of 2020).
Build 1st phase (in Israel) of 22,000 sqft of an eventual total of 270,000 sqft, commercial scale GMP & GAP medical cannabis cultivation & manufacturing facility. Initial budget $2.0M. The first phase of building the 22,000 square foot greenhouse facility was scheduled for completion at the end of March, and with planting to begin shortly thereafter.
EurMed/Canalytics is forming a distribution partnership with FutureMed Clinic in Zurich Switzerland
Located at the heart of Zurich, FurtureMed is a private multidisciplinary medical centre that provides medical cannabis derivative products through certified affiliated clinics throughout the EU. FurtureMed strives to offer quality medical CBD/THC, procured by a team of cannabis specialists using the latest medical methods and technology. FurtureMed’s affiliate clinics offer a spacious and pleasant environment. The well-being of their patients is an essential component.
https://secureservercdn.net/160.153.138.177/p...orDeck.pdf
IsraCann Biosciences (ISCNF) stock price .13 cents headquartered in Vancouver, BC
Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer. Isracann is fully funded to execute on over 230,000 sq ft of hybrid greenhouse.
The company is targeting undersupplied domestic demand combined with an immense international market opportunity through Israel’s new medical cannabis export framework for 2020.
Business Model: Four Pillars
Isracann believes in four verticals to leverage its expertise and scale its business
Cultivation
• Architectural design reviewed by Security consultant and Best Practices consultant.
• Designs submission to Israeli Land Authority.
• Application submission to use land as a joint venture.
• Land inspection by the Israeli Land Authority.
• Specific Genetics offtake program designed to provide highest quality gene material within Israel.
• EU GMP certified packing/drying facility targets highest quality product for domestic and export markets.
Manufacturing
• ISL/EU GMP Manufacturing Processes
• Strategic LOI with Israeli manufacturer defines a clear path to in-country revenue.
• Sourcing additional capacity to meet future demand.
• Low-cost production (est. $0.40/gram).
• IMC-GAP/GSP certified for export compliance.
• Production layout offers excellent modularity for irrigation, electrical distribution and maintenance.
• Ideal climate for industrial scale cultivation.
Distribution
• Israel’s massive domestic undersupply drives regional demand.
• Proximity to the EU allows efficient export under new legislation (January 2019).
• Strategic distribution partner provides practical intermediate multinational trans-shipment entry point.
• Product access to Germany, United Kingdom, Poland & Denmark.
• Existing product lines provide access to domestic and export markets.
Branding
• Israel is recognized worldwide as a center for excellence in agronomy, research, genetics, manufacturing and quality assurance.
• Regional expertise allows for branding differentiation that resonates across the globe.
• Brand positioning will focus on high quality “made in Israel Cannabis.”
• Israeli brand will aid positioning of new commercial formulations.
• Build out of Cannabis/CBD product lines will emphasize regional attributes and quality.
https://isracann.com/company/
5
